ArticleJournal of clinical laboratory analysis2020
Aberrant expression of ADAM9 in ovarian cancer and its clinical significance.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- A Theranostic Study ofBioconjugate chemistry · 2026Article
- ADAM9 in tumor biology: molecular functions, clinical implications, and therapeutic targeting.Cellular & molecular biology letters · 2026Review
- NACC1 accelerates the progression of AML by regulating the ADAM9/PI3K/AKT axis.International journal of medical sciences · 2025Article
- Endometriosis and the risk of ovarian cancer: is miR126 the Achille's heel?Archives of gynecology and obstetrics · 2024Article
- Insights Into the Regulation of Gynecological Inflammation-Mediated Malignancy by Metalloproteinases.Frontiers in cell and developmental biology · 2021Review
- Aberrant expression of ADAM9 in ovarian cancer and its clinical significance.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe oncogene a disintegrin and metalloproteinase 9 (ADAM9) was up-regulated in ovarian cancer tissues, and the present study aims to explore the potential diagnostic and prognostic value of ADAM9 in ovarian cancer (OC).
methodsA total of 30 paired fresh OC tumor tissues and the paired-adjacent normal tissue, and 90 formalin-fixed paraffin-embedded (FFPE) OC samples and adjacent normal tissue were collected. The expression of OC in FFPE samples was examined by immunohistochemical methods, and the mRNA expression of ADAM9 in fresh tumor samples was examined by RT-qPCR methods. Receiver operating characteristics curve was drawn to analyze the potential diagnostic value of ADAM9. Kaplan-Meier survival analysis was performed to compare the overall survival (OS) and disease-free survival (DFS) of the ADAM9 positive and negative OC patients.
resultsThe positive rate of ADAM9 in FFPE OC tumor tissue was markedly higher than in the non-tumorous tissue (61/90 vs 47/90), and increased expression level of ADAM9 may associate with higher histological grade, advanced Figo stage and increased risk of metastasis; moreover, the mRNA expression of ADAM9 was also increased in OC tissue compared with the normal tissue (P < .001), and results of ROC analysis suggested that ADAM9 is a sensitive marker for the diagnosis of OC( AUC 0.8389, 95% confidence interval 0.7333 to 0.9445); finally, increased expression of ADAM9 may indicate decreased OS (P = .004) and DFS (P = .014) of the patients.
conclusionA disintegrin and metalloproteinase 9 was up-regulated in OC, and ADAM9 may serve as potential diagnostic and prognostic marker for the diagnosis and treatment of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.